New combo therapy targets hard-to-treat brain metastasis in lung cancer patients
NCT ID NCT07398599
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a higher dose of a targeted therapy (EGFR-TKI) combined with two other drugs for people with advanced lung cancer that has spread to the lining of the brain and worsened on standard treatment. About 30 participants will receive the triple combination to see if it shrinks the brain lining tumors and to track side effects. The goal is to control the disease, not cure it, as ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, China